Correction: Folate receptor-α (FOLR1) expression and function in triple negative tumors.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 20 citations in OpenAlex.

1. Arsenic‑induced BRCA1 CpG promoter methylation is associated with the downregulation of ERα and resistance to tamoxifen in MCF7 breast cancer cells and mouse mammary tumor xenografts.International journal of oncology · 2019
   Article
2. Nanodiamond-based layer-by-layer nanohybrids mediate targeted delivery of miR-34a for triple negative breast cancer therapy.RSC advances · 2018
   Article
3. Engineering Remotely Triggered Liposomes to Target Triple Negative Breast Cancer.Oncomedicine · 2017
   Article
4. Targeting folate receptor alpha for cancer treatment.Oncotarget · 2016
   Review

Corrections and comments

• Erratum for
  Folate receptor-α (FOLR1) expression and function in triple negative tumors.2015 · Aspita, Alvaro Moreno [corrected to Moreno-Aspitia, Alvaro]

Authors and funding

18 authors at 2 institutions in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.